{"denoms":[{"counts":[{"groupId":"BG000","value":"163"}],"units":"Participants"}],"groups":[{"description":"Patients with minimum 3 years of tyrosine kinase inhibitor treatment (first with imatinib and then switched to nilotinib) since initial diagnosis, at least 2 years of nilotinib treatment prior to study entry and who achieved MR4.5 (local laboratory assessment) during nilotinib treatment, and determined by a Novartis designated central PCR lab assessment at screening","id":"BG000","title":"NTCS Phase"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.99","value":"54.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"86"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"77"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"127"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Native American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"}]}